Examining the association between monthly migraine frequency and quality of life: Post hoc analyses of outcomes data from the topiramate migraine trials

被引：0
|
作者：
Diamond, M
Dahlof, C
Mao, L
Rupnow, M
Papadopoulos, G
Greenberg, S
机构：
[1] Diamond Headache Clin Ltd, Chicago, IL USA
[2] Inst Clin Neurosci, Gothenburg, Sweden
[3] Ortho McNeil Pharmaceut, Raritan, NJ USA
[4] Janssen Med Affairs LLC, Titusville, NJ USA
来源：
HEADACHE | 2005年 / 45卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：778 / 778
页数：1
相关论文
共 50 条
  • [21] Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials
    Tobin, Joshua
    Ford, Janet H.
    Tockhorn-Heidenreich, Antje
    Nichols, Russell M.
    Ye, Wenyu
    Bhandari, Rohit
    Mi, Xiaojuan
    Sharma, Karan
    Lipton, Richard B.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 630 - 639
  • [22] Annual indirect cost savings in patients with episodic or chronic migraine: Post-hoc analyses from multiple galcanezumab clinical trials
    Ford, J. H.
    Tockhorn-Heidenreich, A.
    Nichols, R. M.
    Ye, W.
    Bhandari, R.
    Tobin, J. A.
    Lipton, R. B.
    HEADACHE, 2021, 61 : 54 - 55
  • [23] Efficacy of topiramate for the prevention of migraine in patients reporting symptoms of aura or migraine without aura: Pooled data from 3 placebo-controlled trials
    Pascual, J.
    Silberstein, S.
    Mao, L.
    Greenberg, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 76 - 76
  • [24] Efficacy of topiramate for the prevention of migraine in patients reporting symptoms of aura or migraine without aura: Pooled data from three placebo-controlled trials
    Silberstein, S
    Pascual, J
    Mao, L
    Greenberg, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S88 - S88
  • [25] Efficacy of topiramate for the prevention of migraine in patients reporting symptoms of aura or migraine without aura: Pooled data from 3 placebo-controlled trials
    Silberstein, S
    Pascual, J
    Mao, L
    Greenberg, S
    HEADACHE, 2005, 45 (06): : 824 - 824
  • [26] Monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201)
    Johnston, K. M.
    Harris, L.
    Powell, L.
    Popoff, E.
    Coric, V
    L'Italien, G. J.
    Schreiber, C. P.
    HEADACHE, 2021, 61 : 132 - 133
  • [27] Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies
    Martin, Vincent T.
    Ahmed, Zubair
    Hochstetler, Helen M.
    Baygani, Simin K.
    Dong, Yan
    Hauck, Paula M.
    Khanna, Rashna
    CLINICAL THERAPEUTICS, 2021, 43 (06) : 1066 - 1078
  • [28] Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
    Doty, Erin Gautier
    Krege, John H.
    Jin, Leah
    Raskin, Joel
    Singh, Rashmi B. Halker
    Kalidas, Kavita
    CEPHALALGIA, 2019, 39 (12) : 1569 - 1576
  • [29] Sustained response of galcanezumab in migraine prevention: Patient--level data from a post hoc analysis in patients with episodic or chronic migraine
    Tepper, Stewart J.
    Dong, Yan
    Vincent, Maurice
    Wietecha, Linda A.
    HEADACHE, 2023, 63 (10): : 1380 - 1390
  • [30] Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
    Stewart J Tepper
    Messoud Ashina
    Uwe Reuter
    Yngve Hallström
    Gregor Broessner
    Jo H Bonner
    Hernan Picard
    Sunfa Cheng
    Denise E Chou
    Feng Zhang
    Jan Klatt
    Daniel D Mikol
    The Journal of Headache and Pain, 2021, 22
12345